Scholarlink

Background <p>Current understanding of neoadjuvant immunochemotherapy for locally advanced esophageal squamous cell carcinoma (ESCC) lacks high-level evidence. This study provides additional efficacy data for this treatment regimen.</p> Methods <p>Clinical trials investigating neoadjuvant tislelizumab plus chemotherapy in locally advanced ESCC were identified through literature search. Raw data from investigators were pooled for analysis. Primary endpoint was pCR; secondary endpoints included MPR, R0 resection rate, EFS, DFS, and OS.</p> Results <p>Six studies involving 306 patients were analyzed; 275 (89.9%) underwent surgery. Among surgical patients, pCR rate was 25.5% and MPR rate was 49.5%. Most patients (98.5%) achieved R0 resection. At median follow-up of 31.3&#xa0;months, median EFS, DFS, and OS were not reached. The 1-/2-/3-year rates were: EFS 81.8%/66.9%/59.1%; DFS 79.0%/68.7%/62.3%; and OS 91.7%/77.5%/73.4%. Tislelizumab dose intensity correlated with MPR. MPR and R0 resection were independent prognostic factors for EFS and OS, while pathological staging was associated with DFS and OS.</p> Conclusions <p>Neoadjuvant tislelizumab combined with chemotherapy demonstrated promising efficacy with encouraging pathological responses and survival outcomes in locally advanced ESCC, supporting clinical application.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Long-term outcome of neoadjuvant tislelizumab plus chemotherapy in locally advanced esophageal squamous cell carcinoma

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年12月18日

查看全文
  • Hao Yin,
  • Xinyu Yang,
  • Yujie Chen,
  • Hongtao Duan,
  • Jie Wang,
  • Xuqiang Liao,
  • Guangyu Yao,
  • Fei Liang,
  • Hong Fan,
  • Gao Li,
  • Yihua Sun,
  • Xiaolong Yan,
  • Peiyuan Wang,
  • Lijie Tan

摘要

Background

Current understanding of neoadjuvant immunochemotherapy for locally advanced esophageal squamous cell carcinoma (ESCC) lacks high-level evidence. This study provides additional efficacy data for this treatment regimen.

Methods

Clinical trials investigating neoadjuvant tislelizumab plus chemotherapy in locally advanced ESCC were identified through literature search. Raw data from investigators were pooled for analysis. Primary endpoint was pCR; secondary endpoints included MPR, R0 resection rate, EFS, DFS, and OS.

Results

Six studies involving 306 patients were analyzed; 275 (89.9%) underwent surgery. Among surgical patients, pCR rate was 25.5% and MPR rate was 49.5%. Most patients (98.5%) achieved R0 resection. At median follow-up of 31.3 months, median EFS, DFS, and OS were not reached. The 1-/2-/3-year rates were: EFS 81.8%/66.9%/59.1%; DFS 79.0%/68.7%/62.3%; and OS 91.7%/77.5%/73.4%. Tislelizumab dose intensity correlated with MPR. MPR and R0 resection were independent prognostic factors for EFS and OS, while pathological staging was associated with DFS and OS.

Conclusions

Neoadjuvant tislelizumab combined with chemotherapy demonstrated promising efficacy with encouraging pathological responses and survival outcomes in locally advanced ESCC, supporting clinical application.